Caring for Behavioral Symptoms of Dementia (CBD): A New Investigation into Cannabidiol for the Treatment of Anxiety and Agitation in Alzheimer's Dementia
Rosain Ozonsi,Julia Merrill,Andre Nguyen,Ipsit Vahia,Rosemary Smith,Regan Patrick,David Harper,Brent Forester,Staci Gruber
DOI: https://doi.org/10.1016/j.jagp.2024.01.172
2024-04-01
Abstract:Introduction Alzheimer's disease (AD) is a neurodegenerative disorder that currently affects approximately 6.7 million Americans ages 65 and older. In addition to cardinal memory/cognitive changes, neuropsychiatric symptoms (NPS) are highly prevalent in AD (∼97% of patients) and are a significant source of caregiver burden. Anxiety is one of the most common NPS in AD, with prevalence estimates ranging from 25% to 70%. It is often closely associated with agitation, another prominent NPS characterized by problematic behaviors like combativeness and resistance to care, which further increases both caregiver burden and the need for higher levels of care (e.g., hospitalization). Despite the prevalence of anxiety and agitation in this population, there is currently only one FDA-approved medication for agitation, and none for other behavioral/psychological symptoms of dementia, underscoring the need to develop treatments that are both safe and effective. Toward that end, cannabidiol (CBD), a non-intoxicating constituent of cannabis, often touted for its therapeutic benefit and low side effect profile, is a potential treatment for older adults with AD experiencing anxiety or agitation. Data from both animal and human studies indicate CBD can reduce stress and anxiety with few adverse effects reported, and preliminary studies have demonstrated CBD's potential neuroprotective properties by inhibiting tau hyperphosphorylation - a central facet of AD pathophysiology. To date, however, no human studies have investigated the effects of CBD on anxiety or agitation in AD patients. Methods This 8-week, open label clinical trial is designed to assess the safety and efficacy of a custom-formulated high-CBD/low-THC sublingual solution as a treatment for anxiety and agitation in 12 older adults (ages 55-90) with a clinical diagnosis of mild to moderate dementia due to Alzheimer's disease. Primary anxiety outcome measures include the anxiety domain of the Neuropsychiatric Inventory - Clinician Version (NPI-C), Generalized Anxiety Disorder-7 Item Scale (GAD-7), and the Beck Anxiety Index (BAI). Safety outcomes are assessed using a number of measures evaluating potential side effects, adverse events, and cognition. Additional exploratory measures include agitation and aggression domains on the NPI-C, scores on the Cohen-Mansfield Agitation Inventory (CMAI), and caregiver burden using the Zarit Caregiver Burden Interview. Results Thus far, five patients have completed the 8-week trial, and all have demonstrated a reduction in anxiety relative to baseline, with some patients also demonstrating improvements in cognition. Specifically, informant and clinician-rated measures of anxiety indicate substantial improvement over the trial period. On the BAI, all study partners reported observing a decrease in symptoms of anxiety, ranging from 29% to 100% symptom reduction. Similarly, improvements in overall anxiety are evident on the clinician-rated NPI-C (based on informant reports and direct patient observation), with reductions ranging from 60% to 88%. Results from patient self-report scales are more variable overall, with 4 of 5 patients endorsing a decrease in symptoms of anxiety on the BAI (30% to 100% reduction) and one patient reporting an increase of 50%. Data from our exploratory aim focused on agitation is consistent with our primary outcome data, as all five patients showed reductions in agitation symptoms as measured by the CMAI. No patients or study partners have reported any serious adverse events. Conclusions While data collection is still ongoing, patients who have completed this trial have exhibited reductions in anxiety symptoms. These improvements are most evident on scales that primarily rely on reports from study partners, namely the NPI-C anxiety domain, and the caregiver-rated BAI. This highlights the importance of having a multiple-reporter system in studies involving patients with mild to moderate AD, though it should be noted that broadly similar patterns are evident on our patient self-report scales as well. Results from this study will help inform a planned, randomized, placebo-controlled trial aimed at assessing the clinical efficacy and safety of high-CBD products in older adults with AD.
psychiatry,geriatrics & gerontology,gerontology